ALLMedicine™ Liver Tumors Center

May 11th, 2022 - Hepatic hemangiomas (HH) are the most common vascular tumors of the liver. It is important to distinguish hemangiomas from malignant liver tumors. The patients 0 to 1 years old, were diagnosed with HH and followed up in the oncology outpatient cli...

May 11th, 2022 - Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant tumor syndrome with a high degree of heterogeneity in clinical phenotypes, generally involving the parathyroid, anterior pituitary, and enteropancreas. In recent years, severa...

May 4th, 2022 - Shp2 is the first identified pro-oncogenic tyrosine phosphatase that acts downstream of receptor tyrosine kinases (RTK) to promote Ras-Erk signaling. However, this phosphatase was also shown to be anti-tumorigenic in hepatocellular cancer (HCC). T...

May 2nd, 2022 - This trial is a single arm, non-randomized prospective trial. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Subjects will then be followed for 30 day...

Apr 27th, 2022 - Thrombocytopenia is a known surrogate marker for cirrhosis and portal hypertension and has been associated with increased risk of poor perioperative outcomes when studied in "open" operations. This study was undertaken to assess thrombocytopenia a...

Nov 18th, 2020 - Hepatectomy is standard treatment for colorectal liver metastases; however, it is unclear whether liver metastases from other primary cancers should be resected or not. The Japanese Society of Hepato-Biliary-Pancreatic Surgery therefore created cl...

May 2nd, 2022 - This trial is a single arm, non-randomized prospective trial. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Subjects will then be followed for 30 day...

Apr 19th, 2022 - This prospective, single-arm single center study will provide clinical data for the Neuwave Medical Microwave Ablation System and accessories. Individuals who undergo microwave ablation of liver tumors who meet study entry criteria, will be enroll...

Apr 15th, 2022 - Advanced metastatic hepatocellular carcinoma (HCC) is not treatable by surgical approaches or locoregional therapies such as hepatic artery hemoembolization or radiofrequency ablation (RFA) which are effective in controlling localized tumors. Tran...

Mar 9th, 2022 - Primary liver cancer is the leading cause of cancer worldwide. The majority of primary liver cancers are hepatocellular carcinoma (HCC) and occur in the setting of cirrhosis of the liver. Body fat and systemic inflammation are determinants of HCC ...

Feb 15th, 2022 - A retrospective chart review of patients who have the diagnosis of intrahepatic cholangiocarcinoma. Only patients treated at MDMC are included and data will be obtained from Meditech and Epic. A non-identified database of cases with the diagnosis ...

Apr 26th, 2022 - Oncolytic immunotherapy with talimogene laherparepvec (T-VEC; Imlygic) and vusolimogene oderparepvec (RP1) has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration, according to Nik...

Mar 4th, 2022 - Liver cancer is a highly vascularized and one of the most drug resistant forms of solid tumors. Therapeutic options for liver cancer treatment are very limited and the prognosis is poor. Patients get diagnosed at a late stage of liver cancer. Many...

Dec 2nd, 2021 - David L. Bartlett, MD, a renowned cancer researcher and clinician specializing in advanced surgical treatments for abdominal cancers, has reopened his Pittsburgh practice and will begin seeing patients at AHN Cancer Institute – Allegheny General o...

Oct 6th, 2021 - Associate Professor, Surgery The University of Illinois at Chicago Chicago, IL Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal (GI) maligna...

Oct 6th, 2021 - Paul R. Helft, MD Since the FDA approval of Lutathera (lutetium Lu 177 dotatate) in January 2018, other treatments may take a backseat to peptide receptor radionuclide therapy (PRRT) for patients with gastroenteropancreatic (GEP)-neuroendocrine t...